Actinium Pharmaceuticals, Inc.
AMEX:ATNMBiotechnology
Healthcare
$1.64 +15.94%
+$0.22 today
- Market cap
- $51.56M
- Beta
- 0.02
- P/E (TTM)
- 4.4
- EPS (TTM)
- $0.36
52W Low $0.74High $1.74
Volume 0.18M
Average 0.15M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$24.58M
FY 2025 · Annual
Investing Cash Flow
-$104,000.00
FY 2025 · Annual
Financing Cash Flow
-$217,000.00
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (24.77M) | (33.02M) | (48.82M) | (38.24M) | (33.89M) |
| Depreciation & Amortization | 524K | 699K | 790K | 811K | 821K |
| Deferred Income Tax | (1.55M) | 402K | 0 | 0 | 0 |
| Stock-Based Compensation | 1.69M | 2.8M | 3.84M | 5.29M | 9.19M |
| Change in Working Capital | 1.69M | 38.17M | (3.15M) | (932K) | (704K) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.2M | 4.6M | (2.18M) | (387K) | (346K) |
| Other Working Capital | 495K | 33.57M | (972K) | (545K) | (358K) |
| Other Non-Cash Items | 1.55M | (402K) | 0 | 0 | 0 |
| Operating Cash Flow | (20.87M) | 8.64M | (47.34M) | (33.07M) | (24.58M) |
| Capital Expenditures | (133K) | (366K) | (153K) | (11K) | (104K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (133K) | (366K) | (153K) | (11K) | (104K) |
| Debt Repayment | (85K) | (49K) | (4K) | (9K) | (10K) |
| Common Stock Issued | 35.3M | 23.16M | 14.87M | 29.26M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (207K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 6K | 0 | 0 | 75K | 0 |
| Financing Cash Flow | 35.22M | 23.11M | 14.87M | 29.32M | (217K) |
| Effect of Forex Changes | 0 | 0 | (11K) | 0 | 6K |
| Net Change in Cash | 14.22M | 31.39M | (32.63M) | (3.76M) | (24.9M) |
| Free Cash Flow | (21M) | 8.28M | (47.49M) | (33.08M) | (24.68M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$33.9M
+ D&A$821.0K
+ Stock-Based Comp$9.2M
+ Deferred Tax$0
- Working Capital-$704.0K
+ Other Non-Cash$0
= Operating Cash Flow-$24.6M
- Capex-$104.0K
= Free Cash Flow-$24.7M
Analysis
FY2025 free cash flow is -$24.7M. FCF conversion is 72.8% of net income. Operating cash flow was -$24.6M, with capex of -$104.0K. The largest bridge item is Stock-Based Comp at $9.2M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Oct 16, 2026 | |
| 3 | Initial statement of beneficial ownership | Oct 16, 2026 | |
| 8-K | Current report | Oct 15, 2026 | |
| DEF 14A | DEF 14A filing | Oct 15, 2026 | |
| ARS | ARS filing | Oct 15, 2026 |
Does ATNM generate free cash flow?
Actinium Pharmaceuticals, Inc. (ATNM) generated -$24.68M of free cash flow in fiscal 2025.
How much operating cash flow does ATNM produce?
Operating cash flow was -$24.58M, before capital expenditures of $104,000.00.
Continue the stock analysis
Jump to another research area for this company.